NCT05369949View on ClinicalTrials.gov

DEX vs SEVO in Congenital Heart Surgery

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

January 5, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Heart Defects, Congenital
Interventions
DRUG

DEX group

Participants will receive a dexmedetomidine infusion in addition to low dose sevoflurane anesthesia.

OTHER

Control group

Participants will receive general anesthesia based on institutional's practice with commonly used doses of sevoflurane.

All Listed Sponsors
lead

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER